News coverage about Cerus (NASDAQ:CERS) has been trending somewhat positive on Thursday, Accern Sentiment reports. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cerus earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.2274330286295 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news articles that may have effected Accern Sentiment’s analysis:

A number of equities research analysts have issued reports on CERS shares. Zacks Investment Research upgraded shares of Cerus from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a research note on Wednesday, November 8th. BTIG Research reiterated a “neutral” rating on shares of Cerus in a research note on Friday, December 8th. BidaskClub downgraded shares of Cerus from a “hold” rating to a “sell” rating in a research note on Tuesday. Cowen set a $6.00 price objective on shares of Cerus and gave the stock a “buy” rating in a research note on Thursday, October 5th. Finally, Robert W. Baird reiterated a “buy” rating and set a $5.00 price objective on shares of Cerus in a research note on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $6.17.

Shares of Cerus (CERS) opened at $3.80 on Thursday. Cerus has a one year low of $1.93 and a one year high of $5.21. The company has a current ratio of 3.71, a quick ratio of 3.11 and a debt-to-equity ratio of 0.80.

Cerus (NASDAQ:CERS) last posted its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03. Cerus had a negative net margin of 159.35% and a negative return on equity of 142.18%. The company had revenue of $10.80 million for the quarter, compared to the consensus estimate of $11.95 million. During the same period last year, the company posted ($0.14) EPS. The firm’s quarterly revenue was up 5.9% compared to the same quarter last year. analysts expect that Cerus will post -0.59 EPS for the current year.

WARNING: This piece of content was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at

About Cerus

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Insider Buying and Selling by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with Analyst Ratings Network's FREE daily email newsletter.